The White House released a report estimating that its Most Favored Nation (MFN) drug pricing framework could generate hundreds of billions of dollars in savings over the next decade, driven by lower U.S. drug prices tied to international benchmarks.
The MFN framework is a drug pricing approach that seeks to align prices for certain prescription drugs in the U.S. with the lowest prices paid in other wealthy countries. Rather than functioning as a single statutory price-setting rule, the current model relies on a combination of voluntary agreements with pharmaceutical manufacturers and targeted pricing mechanisms within federal programs, including Medicaid and future drug launches. The administration said the framework includes agreements with a group of manufacturers participating in the initiative, with coverage focused on selected high-cost drugs and specific federal purchasing channels rather than a universal price mandate.
Under the framework, participating drugmakers agree to offer eligible medicines at prices linked to international reference levels to narrow the long-standing gap between U.S. drug costs and prices abroad. The report notes that outcomes would depend in part on manufacturer participation rates and the extent of price differentials between the U.S. and comparable countries, making projected savings sensitive to assumptions about uptake and global pricing spreads.
The MFN concept has circulated in U.S. drug pricing policy for years. A prior version was advanced in 2020 during the Trump administration as a Medicare Part B payment demonstration model, but it was blocked in court and later withdrawn under the Biden administration before it was implemented.
The current iteration differs in structure and scope, relying less on a single Medicare reimbursement mechanism and more on a hybrid approach that combines voluntary manufacturer participation with pricing adjustments across selected federal programs. While Medicare Part B drugs were central to earlier proposals, the current framework places greater emphasis on Medicaid savings, with Medicare treated more as a reference point than the primary implementation channel.
According to the White House report, the MFN framework is projected to generate approximately $529 billion in total savings over 10 years, including $64.3 billion in projected Medicaid savings over the same period. The estimates are based on modeled assumptions, including international price differentials, anticipated manufacturer participation, and expected uptake across eligible drug categories. As a result, the figures reflect projected fiscal impacts rather than realized spending reductions.
The report also suggests potential downstream effects on pharmaceutical pricing strategies, including how manufacturers may set launch prices globally in response to international reference pricing pressure.
The framework is expected to have implications for high-cost drug classes, particularly GLP-1 receptor agonists used in diabetes and weight loss, which have become one of the fastest-growing drivers of prescription drug spending in recent years. Fertility treatments and related medications represent another area of attention, as costs for assisted reproductive therapies continue to rise and coverage remains uneven across insurers, leaving patients more exposed to out-of-pocket spending.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.